R&D Systems™ Recombinant Human Lymphotoxin alpha1/beta2 Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human Lymphotoxin alpha1/beta2 Protein is derived from HEK293. The Recombinant Human Lymphotoxin alpha1/beta2 Protein has been validated for the following applications: Bioactivity.

Specifications

• For Use With (Application): Bioactivity
• Gene ID (Entrez): 4049
• Molecular Weight (g/mol): Observed M.W.: 65-76kDa, reducing conditions, Theoretical M.W.: 61kDa
• Quantity: 25 μg
• Source: Human embryonic kidney cell,HEK293-derived human Lymphotoxin protein, (N-terminus) rhLT alpha (Leu35-Leu205) Accession &Num; P01374 GGGGS rhLT beta (Gln49-Gly244) Accession &Num; Q06643 GGGGS rhLT beta (Gln49-Gly244) Accession &Num; Q06643 (C-terminus)
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU per 1μg of the protein by the LAL method.
• Common Name: Lymphotoxin
• Gene Symbol: LTA
• Biological Activity: Measured by its ability to induce IL-8 secretion by A375 human melanoma cells. The ED50 for this effect is typically 3-15ng/mL.
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Expression System: Human embryonic kidney cell, HEK293-derived rhLT alpha (Leu35-Leu205) Accession # P01374, N-terminus; GGGGS; rhLT beta (Gln49-Gly244) Accession # Q06643; GGGGS; rhLT beta (Gln49-Gly244) Accession # Q06643, C-terminus
• Purity or Quality Grade: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining